Darolutamide 'improves survival' in hormone-sensitive prostate cancer
The ARASENS trial provides compelling evidence for adjunctive use of the drug with metastatic disease, researchers say
The addition of darolutamide to standard therapy significantly improves overall survival in men with metastatic, hormone-sensitive prostate cancer, a large international study shows.
Time to developing castration-resistant disease was also much longer among patients given the potent androgen receptor inhibitor versus placebo, according to the researchers.
Given the absence of any major safety signal, investigators in the multicentre phase 3 trial to evaluate the combination said
